Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28490569

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2017 Jul 20
First author
Zinzani PL

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2017 Jul 20;130(3):234-235. doi: 10.1182/blood-2017-05-786293.
    note
    Source null
    related pmid
    28729332
    relationship
    Comment in

Authors and identifiers

  1. name
    Zinzani PL
    type
    Author
  2. name
    Ribrag V
    type
    Author
  3. name
    Moskowitz CH
    type
    Author
  4. name
    Michot JM
    type
    Author
  5. name
    Kuruvilla J
    type
    Author
  6. name
    Balakumaran A
    type
    Author
  7. name
    Zhang Y
    type
    Author
  8. name
    Chlosta S
    type
    Author
  9. name
    Shipp MA
    type
    Author
  10. name
    Armand P
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Zinzani PL
    type
    Author
  2. name
    Ribrag V
    type
    Author
  3. name
    Moskowitz CH
    type
    Author
  4. name
    Michot JM
    type
    Author
  5. name
    Kuruvilla J
    type
    Author
  6. name
    Balakumaran A
    type
    Author
  7. name
    Zhang Y
    type
    Author
  8. name
    Chlosta S
    type
    Author
  9. name
    Shipp MA
    type
    Author
  10. name
    Armand P
    type
    Author
bibliography ids
  1. nci-bib-b112e3b6369719633650a925
book metadata
content sha256
b258d84139183867300b1013c1f9d9d34ceeaa11c6767b14380f56c5f7ca74ed
document type
citation
dois
  1. 10.1182/blood-2016-12-758383
electronic publication date
display
2017 May 10
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28490569
immutable id
pubmed:28490569@b258d84139183867300b1013c1f9d9d34ceeaa11c6767b14380f56c5f7ca74ed
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
3
name
Blood
nlm unique id
7603509
pages
267-270
volume
130
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2017 Jul 20;130(3):234-235. doi: 10.1182/blood-2017-05-786293.
    note
    Source null
    related pmid
    28729332
    relationship
    Comment in
outcomes validated
false
pmid
28490569
provenance
batch id
1c173f0e18be0c6d461b
provider
NCBI PubMed ESummary
record sha256
1b1db7aadffb4c102654865adef939393cd419bacc1dd8b8fdc5700e55cef9d4
response sha256
27a6f8bb5d49a8d376b07e1b1768913c558986bf73de92cdd65c8f05a5fa1e61
retrieved at
2026-09-09T23:47:25.975513+00:00
publication date
display
2017 Jul 20
precision
day
year
2017
publication types
  1. Clinical Trial, Phase I
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28490569/
title
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

Preserved source evidence · Not medical advice